Rosen Law Firm Files Class Action Against Rocket Pharmaceuticals Over Investor Misstatements

Rosen Law Firm Initiates Action Against Rocket Pharmaceuticals (NASDAQ: RCKT) Over Investor Misrepresentations New York—The Rosen Law Firm, a prominent global investor rights legal practice, has issued a reminder to shareholders that a class-action lawsuit has been filed on behalf of those who purchased Rocket Pharmaceuticals' securities (NASDAQ: RCKT) between September 17, 2024, and May 26, 2025. Rocket Pharmaceuticals is a comprehensive, late-stage biotech firm. Investors interested in learning more can submit a form, contact attorney Phillip Kim via email, or call 866-767-3653. The lawsuit alleges that Rocket Pharmaceuticals misled investors regarding the safety and efficacy of its experimental treatment, RP-A501. Specifically, the complaint claims that during the class period, the company made false or misleading statements, or failed to disclose that: (1) RP-A501 was less effective than suggested; (2) modifications to the clinical trial protocol, including the addition of an immunomodulatory agent, increased the risk of serious adverse events; (3) these changes overstated the safety profile and clinical prospects; and (4) overall, the company's public statements were materi...